CN109125489A - A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia - Google Patents

A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia Download PDF

Info

Publication number
CN109125489A
CN109125489A CN201811246774.7A CN201811246774A CN109125489A CN 109125489 A CN109125489 A CN 109125489A CN 201811246774 A CN201811246774 A CN 201811246774A CN 109125489 A CN109125489 A CN 109125489A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
radix
leukaemia
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811246774.7A
Other languages
Chinese (zh)
Inventor
张天寿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201811246774.7A priority Critical patent/CN109125489A/en
Publication of CN109125489A publication Critical patent/CN109125489A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/20—Aceraceae (Maple family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/35—Caprifoliaceae (Honeysuckle family)
    • A61K36/355—Lonicera (honeysuckle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/78—Saururaceae (Lizard's-tail family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a kind of pharmaceutical compositions and its preparation method and application for treating tumour and leukaemia, belong to tcm field.The pharmaceutical composition is made of the raw material of following parts by weight: 15-30 parts of 5-10 parts of nine bursts of 30-50 parts of oxen, 10-15 parts of rough gentian grass roots, ginseng or American Ginseng, 50-100 parts of Radix Salviae Miltiorrhizae, 30-100 parts of Radix Angelicae Sinensis, radix rehmanniae preparata or Radix Rehmanniae, 15-30 parts of Radix Notoginseng, 10-20 parts of honeysuckle, 10-20 parts of swertia mileensis and 20-30 parts of cordate houttuynia.The entire prescription of the present invention has good curative effect to tumour, especially brain tumor, breast cancer and leukaemia, also has certain booster action to cardiovascular and cerebrovascular disease postoperative rehabilitation.

Description

A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia
Technical field
The present invention relates to a kind of pharmaceutical composition, especially a kind of pharmaceutical composition for treating tumour and leukaemia is also related to And its preparation method and application, belong to tcm field.
Background technique
The cancer of early stage generally selects operative treatment, but postoperative the problem of still suffering from recurrence and transfer.And middle and advanced stage The primary treatments of cancer are still based on chemotherapy at present.
Breast cancer is one of the most common malignant tumors in women, and according to statistics, disease incidence accounts for the various malignant tumours of whole body 7-10%, be only second to uterine cancer in women, its morbidity it is often related with heredity and 40-60 years old between, before and after menopause Women's disease incidence is higher.The malignant tumour in breast galandular epithelium tissue usually occurs.It is that one kind seriously affects women's physical and mental health Even one of the most common malignant tumour of threat to life.
In recent years, intracranial tumors disease incidence is in rising trend, and according to statistics, intracranial tumors account for about the 5% of general tumour, accounts for The 70% of virgin tumour, and other malignant tumours finally have 20-30% and are transferred to encephalic, due to the infiltrative growth of its expansion, Encephalic is when according to certain space, no matter its property is benign or pernicious, certainly will all intracranial pressure be made to increase, and oppresses brain tissue, Cause nervous centralis to damage, jeopardizes patient vitals.
The treatment of Pituitary adenoma mainly includes three kinds of operation, drug and radiotherapy treatment methods.Just because of no one Kind method can achieve the purpose for curing each hypophysoma completely, so various treatment methods cut both ways.About radiotherapy, by Belong to adenoma in hypophysoma, itself is poor to the sensibility of radiotherapy, and nearly pituitary function occur low by the patient of 70-80% after radiotherapy Subtract, reduce the quality of life of patient, operation is remaining, is not resistant to operation, is insensitive to drug, having so radiotherapy is only applicable to Suffering from the disease altogether can not undergo surgery or the patient of drug therapy.
The drug for clinically treating all kinds of tumours at present mainly has chemicals, but since chemotherapeutics toxicity is big, is killing Also human autoimmunes' cell such as kill leucocyte, lymphocyte of non-selectivity while dead tumour cell, causes patient normal Often due to being lowly complicated by infection because of autoimmune ability, patient uses erious adverse reaction, and the course for the treatment of is long, costly, makes in clinic There is biggish limitation in.
Traditional Chinese medicine has unique advantage in terms for the treatment of tumour, has poison is secondary to make by the natural class drug of representative of Chinese medicine With the features such as small, action target spot is various, tolerance is good, more and more it is taken seriously in terms for the treatment of tumour.Chinese medicine thinks, tumour Formation is that qi and blood fortune is obstructed for regular disorder, channels and collaterals, and qi and blood pent-up is formed in a certain position, and corporal parts will appear. But the anti-breast cancer Chinese medicine compound prescription dosage reported at present is larger, impurity component is more, and curative effect is unobvious.
Traditional Chinese medical herbal treatment leukaemia also in recent years more research, and for Chinese medicine at present to the treatment of leukaemia, existing special side is special Medicine treatment, also there is Coryza Treated by Syndrome Differentiation；Existing combination doctor trained in Western medicine chemotherapy, is also applied alone Chinese medicine to treat.Tang Youjun Chinese medicine compound prescription and chemotherapy The method that combines treats more than 700 example leukaemics, it is divided into 4 types: type of deficiency of both QI and YIN by theory of traditional Chinese medical science, with Radix Astragali, when Return, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Poria cocos, radix rehmanniae recen, Radix Ophiopogonis, field thistle, oldenlandia diffusa, cortex moutan, fructus amomi, rhizoma polygonati, Radix Glycyrrhizae treatment；Qi and blood It is double lose types, with Radix Astragali, Radix Angelicae Sinensis, Rehmannia glutinosa, radix rehmanniae recen, Radix Paeoniae Alba, fructus lycii, donkey-hide gelatin, Radix Codonopsis, fructus amomi, oldenlandia diffusa, field thistle, Eclipta prostrata treatment；To extreme noxious heat, treated with radix rehmanniae recen, cortex moutan, gypsum, honeysuckle, rhizoma imperatae, dried orange peel, Radix Glycyrrhizae；To spleen Kidney deficiency is treated with Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Radix Astragali, fructus amomi, Semen Cuscutae, fructus lycii, the fruit of glossy privet.
Meanwhile the treatment of cardiovascular and cerebrovascular disease at present is still based on doctor trained in Western medicine, but the postoperative rehabilitation stage, there is no auxiliary Drug helping, pharmacological property is mild.
In addition, existing Chinese medicine also tends to be to have the effect of single, therefore, it is good to research and develop a kind of antitumous effect, Dosage is few, and has no toxic side effect, while can treat leukaemia and assist the medicine group of cardiovascular and cerebrovascular disease postoperative rehabilitation Object is closed to be of great significance.
Summary of the invention
In order to solve the above technical problem, the present invention provides a kind of pharmaceutical compositions and its system for treating tumour and leukaemia Preparation Method and application, the Chinese medicine can not only effectively treat brain tumor and breast cancer, also have treatment leukaemia and auxiliary cardiovascular and cerebrovascular The effect of disease postoperative rehabilitation.Concrete scheme of the invention is as follows:
A kind of pharmaceutical composition for treating tumour and leukaemia, it is characterised in that: be made of the raw material of following parts by weight:
5-10 parts of nine bursts of 30-50 parts of oxen, 10-15 parts of rough gentian grass roots, ginseng or American Ginseng, 50-100 parts of Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis 30-100 Part, radix rehmanniae preparata or 15-30 parts of Radix Rehmanniae, 15-30 parts of Radix Notoginseng, 10-20 parts of honeysuckle, 10-20 parts of swertia mileensis and 20-30 parts of cordate houttuynia.
The preparation method of above-mentioned pharmaceutical composition of the present invention, comprising the following steps: weigh original in parts by weight Material is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get described pharmaceutical composition is arrived.
Further, dosage is each 100ml-500ml, 3 times a day.
Further, combine described pharmaceutical composition with pharmaceutically acceptable carrier be prepared into oral solution, granule, The drug of capsule or Tabules.
The invention further relates to above-mentioned pharmaceutical composition preparing it is antitumor, treatment treatment cardiovascular disease or treatment it is white Application in the drug of blood disease.
Chinese medicine composition provided by the invention, Fang Zhong:
Nine bursts of oxen, mildly bitter flavor are cool in nature；It is clearing heat and detoxicating, cough-relieving, analgesic；For cough with lung heat, mazoitis, parotitis, carbuncle furuncle malignant boil Sore, traumatic injury.
Radix gentianae, bitter are cold in nature.Return liver, gallbladder channel.Containing gentiopicrin (Gentiopicrin), Swertiamarin (Swertiamarin), sweroside (Sweroside), trilobatin (Trifloroside), amarogentin (Amarogentin), four Acetyl gentiopicrin (Gentiopicroside tetraacetate), amaroswerin (Amaroswerin)；Gentioflavine (Gentioflavine), erythricine (Gentianine), gentianidine (Gentianidine), gentianol (Gentianol), gentianose (Gentianose), cupreol (β-Sitosterol) etc., there is antitumor effect.
Radix Salviae Miltiorrhizae, bitter are slightly cold.Converge to heart and liver channels.It is usually used in chest impediment and cardialgia, stomach duct and abdomen hypochondriac pain, the accumulation of lump in the abdomen lump in the abdomen, hot numbness pain, the heart Tired egersis, irregular menstruation, dysmenorrhea menostasis, sore swell and ache curative.
Ginseng, sweet in flavor, slight bitter are warm-natured, flat.Returns spleen, lung channel, the heart channel of Hang-Shaoyin.Tonifying Qi, prevent prolapse are promoted the production of body fluid, and are calmed the nerves, intelligence development.Cure mainly body Void is intended to take off, cold weak pulse of limb, spleen eating less, and the deficiency syndrome of the lung is breathed with cough, injury thirst, Heat Diabetes, and prolonged illness void is thin, insomnia of palpitating with fear, impotence palace It is cold；Heart failure, cardiogenic shock.For dyspnea with shortness of breath, palpitation and amnesia, thirsty hidrosis, deficiency of food is powerless, all acute and chronic diseases And caused shock, collapse after blood loss.It reinforces vital energy, prevent prolapse and engender liquid is calmed the nerves.It is deficient to control internal lesion caused by overexertion, deficiency of food, burnout, regurgitation and emesis, Stool slipping diarrhea, cough of deficient and syndrome characterized by dyspnea, spontaneous perspiration sudden collapse, palpitation with fear, amnesia, dizziness and headache, impotence, frequent micturition are quenched one's thirst, woman uterine bleeding, and children are slow Frightened and perennial and irrecoverable weakness, the card of all qi-blood-body fluid deficiencies.
American Ginseng, sweet slight bitter are cool.Beneficial lung yin is cured mainly, the clear fire of deficiency type promotes the production of body fluid to quench thirst.It controls the deficiency syndrome of the lung to cough long, blood loss, dry throat and mouth, Abnormal heat is tired of tired.
Radix Angelicae Sinensis, nature and flavor: sweet, pungent, warm；It enriches blood；Promoting blood circulation；Menstruction regulating and pain relieving；Moisturizing dryness and lubricating intestine.The main all cards of the deficiency of blood；Irregular menstruation；Through It closes；Dysmenorrhea；Abdominal mass knot is poly-；Metrorrhagia and metrostaxis；Asthenia cold abdominalgia；Flaccidity syndrome and arthralgia syndrome；Numbness；Intestines are dry and shit is difficult；Weight after dysentery with bloody stool；Ulcer sores；Fall and flutters Damage；There are also antitumaous effects.
Radix rehmanniae preparata, sweet, tepor；Return liver and kidney channel；It enriches blood yin-nourishing, life essence-filling, marrow-benefitting.
Radix Rehmanniae, it is sweet, it trembles with fear；Return heart, liver, kidney channel.Clearing heat and cooling blood, yin-nourishing are promoted the production of body fluid.For the deep red polydipsia of pyreticosis tongue, yin asthenia generating intrinsic heat, Hectic fever due to yin labor heat, Heat Diabetes are spitted blood, bleeding from five sense organs or subcutaneous tissue, spot dermexanthesis.
Radix Notoginseng, sweet, slight bitter, temperature.Return liver, stomach meridian.For spitting blood, haematemesis, bleeding from five sense organs or subcutaneous tissue, hematochezia, metrorrhagia and metrostaxis, traumatic hemorrhage, chest and abdomen Shouting pain, tumbling and swelling.
Honeysuckle, it is cold in nature, it is sweet in flavor, enter lung, the heart, stomach meridian, has effects that clearing heat and detoxicating, anti-inflammatory, qi-restoratives treats wind, cure mainly swollen Completely descend disease, warm disease heating, the diseases such as heat toxin large carbuncle and tumour.It is for dizziness, thirst, sweating and boring, enteritis, bacterium Dysentery, morbilli, pneumonia, encephalitis, epidemic meningitis, acute mastitis, septicemia, ecphyaditis, skin infection, ulcer boils, erysipelas, the parotid gland The illnesss such as inflammation, suppurative tonsillitis have certain curative effect.
Swertia mileensis, it is bitter, sweet, it trembles with fear.Return liver, gallbladder, bladder meridian.Clear liver and gallbladder, clearing heat and promoting diuresis.
Cordate houttuynia, clearing heat and detoxicating, inducing diuresis to remove edema.Control pneumonia, lung abscess, hot dysentery, malaria, oedema, stranguria syndrome, leukorrhea, carbuncle swells, Hemorrhoid, rectal prolapse, eczema, the favus of the scalp, scabies.
Compared with prior art, beneficial effects of the present invention are as follows:
(1) present invention is based on nine bursts of oxen, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis, cordate houttuynia, wherein nine bursts of oxen, Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis are cooperated by above-mentioned amount There is the effect of good activating microcirculation and removing stasis medicinal, mild blood vessel, entire prescription can consolidate body substrate, and a few taste medicine synergistic effects can help Positive reinforcing is aided with other compositions, and entire prescription has good curative effect to tumour, especially brain tumor, breast cancer and leukaemia, Also there is certain booster action to cardiovascular and cerebrovascular disease postoperative rehabilitation.
(2) present invention can reduce tumor patient pain, extend life cycle.
(3) it is excellent to prove that pharmaceutical composition of the invention has rat pituitary tumor model for brain tumor experiment and clinical test Therapeutic effect, it is curative for effect reliable.
(4) present invention is highly-safe, has no toxic side effect.
Specific embodiment
It is clearly and completely described below in conjunction with the technical solution in embodiment, it is clear that described embodiment is only It is only rather than whole example to a part of example of the present invention.Based on the embodiments of the present invention, ordinary skill people Member's every other embodiment obtained under that premise of not paying creative labor, shall fall within the protection scope of the present invention.
Embodiment 1
The treatment tumour of the present embodiment and the pharmaceutical composition of leukaemia, are made of the raw material of following parts by weight:
Nine bursts of 40 parts of oxen, 12 parts of rough gentian grass roots, 8 parts of ginseng, 70 parts of Radix Salviae Miltiorrhizae, 50 parts of Radix Angelicae Sinensis, 20 parts of Radix Rehmanniae, 20 parts of Radix Notoginseng, gold and silver Spend 15 parts, 15 parts of swertia mileensis and 25 parts of cordate houttuynia.
Raw material is weighed in parts by weight, is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get arriving Described pharmaceutical composition.Dosage is each 200ml, 3 times a day.
Embodiment 2
The treatment tumour of the present embodiment and the pharmaceutical composition of leukaemia, are made of the raw material of following parts by weight:
Nine bursts of 30 parts of oxen, 10 parts of rough gentian grass roots, 5 parts of ginseng, 60 parts of Radix Salviae Miltiorrhizae, 60 parts of Radix Angelicae Sinensis, 15 parts of Radix Rehmanniae, 15 parts of Radix Notoginseng, gold and silver Spend 10 parts, 10 parts of swertia mileensis and 20 parts of cordate houttuynia.
Raw material is weighed in parts by weight, is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get arriving Described pharmaceutical composition.Dosage is each 100ml, 3 times a day.
Embodiment 3
The treatment tumour of the present embodiment and the pharmaceutical composition of leukaemia, are made of the raw material of following parts by weight:
Nine bursts of 45 parts of oxen, 15 parts of rough gentian grass roots, 10 parts of ginseng, 60 parts of Radix Salviae Miltiorrhizae, 60 parts of Radix Angelicae Sinensis, 15 parts of Radix Rehmanniae, 15 parts of Radix Notoginseng, gold and silver Spend 10 parts, 10 parts of swertia mileensis and 20 parts of cordate houttuynia.
Raw material is weighed in parts by weight, is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get arriving Described pharmaceutical composition.Dosage is each 400ml, 3 times a day.
Embodiment 4
The treatment tumour of the present embodiment and the pharmaceutical composition of leukaemia, are made of the raw material of following parts by weight:
Nine bursts of 40 parts of oxen, 12 parts of rough gentian grass roots, 10 parts of American Ginseng, 70 parts of Radix Salviae Miltiorrhizae, 50 parts of Radix Angelicae Sinensis, 20 parts of radix rehmanniae preparata, 20 parts of Radix Notoginseng, gold 15 parts of honeysuckle flower, 15 parts of swertia mileensis and 25 parts of cordate houttuynia.
Raw material is weighed in parts by weight, is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get arriving Described pharmaceutical composition.Dosage is each 200ml, 3 times a day.
Embodiment 5
The treatment tumour of the present embodiment and the pharmaceutical composition of leukaemia, are made of the raw material of following parts by weight:
Nine bursts of 45 parts of oxen, 15 parts of rough gentian grass roots, 10 parts of American Ginseng, 60 parts of Radix Salviae Miltiorrhizae, 60 parts of Radix Angelicae Sinensis, 15 parts of radix rehmanniae preparata, 15 parts of Radix Notoginseng, gold 10 parts of honeysuckle flower, 10 parts of swertia mileensis and 20 parts of cordate houttuynia.
Raw material is weighed in parts by weight, is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get arriving Described pharmaceutical composition.Dosage is each 400ml, 3 times a day.
Embodiment 6
The treatment tumour of the present embodiment and the pharmaceutical composition of leukaemia, are made of the raw material of following parts by weight:
Nine bursts of 30 parts of oxen, 10 parts of rough gentian grass roots, 6 parts of ginseng, 60 parts of Radix Salviae Miltiorrhizae, 60 parts of Radix Angelicae Sinensis, 15 parts of radix rehmanniae preparata, 18 parts of Radix Notoginseng, gold and silver Spend 10 parts, 10 parts of swertia mileensis and 20 parts of cordate houttuynia.
Raw material is weighed in parts by weight, is uniformly mixed, and addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get arriving Described pharmaceutical composition.Dosage is each 100ml, 3 times a day.
7 anti-breast cancer pharmacological evaluation of embodiment
(1), to the inhibiting effect of human breast carcinoma in nude mouse (MCF-7) cell
Experimental method: preparing MCF-7 Human Breast Cancer Cells suspension, adjusts cell concentration, armpit inoculates human milk gland before every mouse is right Cancer MCF-7 cell 5 × 106A/0.2ml is inoculated with 20 altogether, and being randomly divided into treatment group, (having for the offer of the embodiment of the present invention 1 is anti- The Traditional Chinese medicine compound composition of mammary gland cancer activity, 001. gastric infusion of lot number, 2g/kg) and blank group (waiting capacity physiological saline), often It after group 10,24 hours, starts medication, once a day, continuous 24 days, after drug withdrawal, puts to death animal, observation tumour growth situation is simultaneously Tumor tissue weighing is taken, specific experiment the results are shown in Table 1.
Inhibiting effect of the table 1 to human breast carcinoma in nude mouse (MCF-7) cell
(2), external anti-breast cancer activity test
Cell strain: human breast carcinoma (MCF-7) cell；96 orifice plates are purchased from Costar company；RMPI1640 culture medium is public purchased from Gibco Department；DMEM culture medium is purchased from Gibco company；Newborn bovine serum is purchased from Hangzhou Chinese holly company；Thiazolyl blue (MTT) and DMSO are purchased from Amresco company.
Used laboratory apparatus is as follows:
Laboratory apparatus: superclean bench (Suzhou purifies model SW-CJ-IFD), CO2 incubator (SANYO model: XD-101), Microplate reader BIO-RAD (Model NO .550Serial NO.16971).
Used experimental method is as follows:
Experimental method: external anti-human mammary gland is carried out to the Chinese medicine composition that the embodiment of the present invention 1 is prepared using improvement mtt assay Cancer cell experiment: it is 5 × 10 that human breast carcinoma (MCF-7) is digested with pancreatin, is counted, concentration is made4The cell of a/ml is outstanding Liquid.100 μ l cell suspension (every holes 5 × 10 are added in hole every in 96 orifice plates3A cell), 37 DEG C are subsequently placed in, 5%CO2Incubator Middle culture 24 hours；Drug is diluted to required different gradient concentrations with non-fully culture medium, and every hole is added 100 μ L and contains accordingly Medicine culture medium, while negative control group is set up, vehicle control group and positive controls, then 96 orifice plates are placed in 37 DEG C, 5%CO2 It is cultivated 72 hours in incubator.Then 20 μ L MTT (5mg/ml) are added in every hole, continue culture 4 hours, terminate culture, discard training Base is supported, every hole is added 150 μ L DMSO dissolution, mixes gently within shaking table 10 minutes.Enzyme is used under λ=4570nm, two wavelength of 620nm The absorbance i.e. OD value that mark instrument detects every hole calculates the suppression of each drug using the average value of each multiple holes as the OD value of this group of cell Rate processed.
Experimental result shows the Chinese medicine composition that is prepared of the embodiment of the present invention 1, to human breast carcinoma (MCF-7) have compared with Strong inhibiting effect, each dosage group present preferable dose-effect relationship.Experimental result is as shown in table 2.
Inhibiting effect result of the table 2 to human breast carcinoma (MCF-7)
It is provided by the invention that there is anti-human mammary gland cancer activity by above the results showed that relative to conventional pharmaceutical composition Chinese medicine composition significantly inhibit to being transplanted in human breast carcinoma nude mouse, also have obvious inhibit human milk gland in vitro The effect of growth of cancer cells.It is significant anti-human to show that the Chinese medicine composition provided by the invention with anti-human mammary gland cancer activity has The effect of breast cancer can be used for the treatment of breast cancer disease.
Embodiment 8 inhibits brain tumor experiment
Prepare Wistar rat 120, is randomly divided into blank group, control group and experimental group 1-6 group, every group 10.Except blank Group is outer, is all made of estrogen method and prepares Pituitary adenoma model.Meanwhile blank group and control group give physiological saline, and embodiment 1-6 group gives the pharmaceutical preparation prepared in 1-6 of the embodiment of the present invention respectively.Rat is put to death after two weeks, takes out hypophysis, weighs weight Amount.
The result shows that the pituitary average weight of control rats is 3.4 times of blank group, show modeling success；Implement Average weight is respectively less than 2.9 times of blank group in the group of example 1-6 group rat pituitary.There is statistical difference between group.Illustrate this Invention preparation has excellent therapeutic effect to rat pituitary tumor model.
The verifying of 9 toxicity of embodiment
50 healthy mices are selected, weight 80-120g is randomly divided into 5 groups, every group of half male and half female, respectively with the medicine of embodiment 1-6 Preparation made of compositions is administered, and ejection preparation per injection amount is 0.2mL/10g, oral preparation gastric infusion 0.4ml/10g, once in the morning and once at night.After administration 7 days, the mouse of embodiment 1-6 there are no any Novel presentation, and diet is movable good Good, none is dead.Show within the scope of prescription of the invention, drug safety.
10 animal pharmacological experiment of embodiment-is to the effect of Leukemia Model
(1) mouse human leukemia model is established
Nude mice (BALB/C-nu/nu) 110 is taken, weight 16g or so is randomly divided into 3 groups, wherein model group 70, normal control Group 20, solution control group 20.With the sterile liquid of sterile PBS liquid configuration 10mg/ml concentration, give model group mouse with 2mg/ Intraperitoneal injection, continuously injects 2d.After for 24 hours, the cell of the acute B lymphocytic series leukemia cell line in logarithmic phase is taken (Nalm-6 cell), 1000r/min are suspended in sterile PBS after being centrifuged 5min, adjustment cell density to 2 .5 × 107/ml, Tail vein injection 5 × 106/only (200 μ l).Mouse symptom is observed every 1-2d, paralysis occurs with hind leg for morbidity standard.About Occur double hind legs after 18 days to be slow in action, and rapidly develops as paralysis.
(2) experimental model grouping and administration
Drug A group: take model group animal 10, the drug of embodiment 1 is provided, stomach-filling after suspension is made, measures 71mg/ every time Kg, daily stomach-filling 1 time, the adult metering for being converted to 70kg weight is 0 .47g/ days.
Drug B group: take model group animal 10, providing the drug of embodiment 2, stomach-filling after suspension be made, and measures every time The daily stomach-filling of 71mg/kg 1 time, the adult metering for being converted to 70kg weight is 0 .47g/ days.
Drug C group: take model group animal 10, providing the drug of embodiment 3, stomach-filling after suspension be made, and measures every time The daily stomach-filling of 71mg/kg 1 time, the adult metering for being converted to 70kg weight is 0 .47g/ days.
Drug D group: take model group animal 10, providing the drug of embodiment 4, stomach-filling after suspension be made, and measures every time The daily stomach-filling of 71mg/kg 1 time, the adult metering for being converted to 70kg weight is 0 .47g/ days.
Drug E group: take model group animal 10, providing the drug of embodiment 5, stomach-filling after suspension be made, and measures every time The daily stomach-filling of 71mg/kg 1 time, the adult metering for being converted to 70kg weight is 0 .47g/ days.
Drug F group: take model group animal 10, providing the drug of embodiment 6, stomach-filling after suspension be made, and measures every time The daily stomach-filling of 71mg/kg 1 time, the adult metering for being converted to 70kg weight is 0 .47g/ days.
Positive controls:, providing commercially available thymus gland pentapeptide injection by take model group animal 10, daily with the abdominal cavity 3mg/kg note It penetrates 1 time.
Model control group, solution control group, Normal group: every group of animal each 10 are taken, daily stomach-filling physiological saline 71mg/kg。
(3) index checking
The behavior of each group mouse is observed during administration.After stomach-filling 5 days, after 8h fasting for solids and liquids, claim the weight of animals, in super-clean bench after anesthesia Mouse is put to death, lung, liver,spleen,kidney, meninx observation are won.
(4) result
Result above, which can be seen that drug of the present invention, has good recovery and reconstruction for mouse simulated person's Leukemia Model Effect, while there is preferable protection and therapeutic effect to lung, liver, kidney portion.
11 clinical treatment of embodiment
Mass patient caused by hyperplasia of mammary glands caused by endocrine disorder to different symptoms and a variety of causes, takes implementation The drug of one of example 1-6, it is specific such as table 1.
Meanwhile 100 breast mass patients are selected at random, and the drug of one of embodiment 1-6 is taken, it is specific such as table 2.
Table 1
Table 2
Wherein, sick time is existing significant curative effect even rehabilitation within one week of initial stage patient in three months.
100 leukaemics are selected at random, take the drug two weeks of one of embodiment 1-6, it is specific such as table 3.
Table 3
It is clearly better It is effective In vain It is other
Case load 75 20 5
Ratio (%) 75 20 5
100 Patients with Brain Tumors are selected at random, the drug 7 for taking one of embodiment 1-6 is paid, specific such as table 4.
Table 4
Tumor disappearance Tumour reduces It is other
Case load 70 30
Ratio (%) 70 30
100 cardiovascular and cerebrovascular disease postoperative patients are selected at random, the drug 4 for taking one of embodiment 1-6 is paid, specific such as table 5.
Table 5
Recovery from illness It is effective It is other
Case load 80 20
Ratio (%) 80 20
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, it is all in spirit of the invention and Within principle, any modification, equivalent replacement, improvement and so on be should all be included in the protection scope of the present invention.

Claims (5)

1. a kind of pharmaceutical composition for treating tumour and leukaemia, it is characterised in that: be made of the raw material of following parts by weight:
5-10 parts of nine bursts of 30-50 parts of oxen, 10-15 parts of rough gentian grass roots, ginseng or American Ginseng, 50-100 parts of Radix Salviae Miltiorrhizae, Radix Angelicae Sinensis 30-100 Part, radix rehmanniae preparata or 15-30 parts of Radix Rehmanniae, 15-30 parts of Radix Notoginseng, 10-20 parts of honeysuckle, 10-20 parts of swertia mileensis and 20-30 parts of cordate houttuynia.
2. the preparation method of pharmaceutical composition described in claim 1, it is characterised in that: the following steps are included: in parts by weight Raw material is weighed, is uniformly mixed, addition water cover crosses medicinal material surface and boils latter 30 minutes or so to get described pharmaceutical composition is arrived.
3. the preparation method of pharmaceutical composition according to claim 2, it is characterised in that: dosage is each 100ml- 500ml, 3 times a day.
4. the preparation method of pharmaceutical composition as claimed in claim 3, it is characterised in that: by described pharmaceutical composition and pharmaceutically Acceptable carrier combination is prepared into the drug of oral solution, granule, capsule or Tabules.
5. pharmaceutical composition described in one of claim 1-2 is preparing antitumor, treatment treatment cardiovascular disease or is treating white Application in the drug of blood disease.
CN201811246774.7A 2018-10-24 2018-10-24 A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia Pending CN109125489A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811246774.7A CN109125489A (en) 2018-10-24 2018-10-24 A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811246774.7A CN109125489A (en) 2018-10-24 2018-10-24 A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia

Publications (1)

Publication Number Publication Date
CN109125489A true CN109125489A (en) 2019-01-04

Family

ID=64809962

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811246774.7A Pending CN109125489A (en) 2018-10-24 2018-10-24 A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia

Country Status (1)

Country Link
CN (1) CN109125489A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101306118A (en) * 2008-06-13 2008-11-19 袁慧杰 Xuekangfu pill

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101306118A (en) * 2008-06-13 2008-11-19 袁慧杰 Xuekangfu pill

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
马福亭: "《食疗胜似药》", 28 February 2014, 天津科学技术出版社 *

Similar Documents

Publication Publication Date Title
CN101606632B (en) Health care feed for sow in perinatal period
CN100490789C (en) Enteric coated Chinese medicinal capsule for treating cancer and preparation method thereof
CN101342271B (en) Traditional Chinese medicine for treating qi-blood deficiency caused by tumour chemotherapy and preparation method thereof
CN105920514A (en) Traditional Chinese medicinal composition for treating metabolic syndrome
CN101711848B (en) Chinese medicinal composition capable of adjunctively treating tumour
CN102302567B (en) Stagnation-removing and stasis-removing Chinese patent medicine
CN105535859A (en) Traditional Chinese medicine preparation for treating stomach cancer and preparing method thereof
CN108635544A (en) Treat Hashimoto's thyroiditis Chinese medicine composition and its preparation method and application
CN103721196A (en) Traditional Chinese medicine composition for treating liver cancer
CN101564464B (en) Chinese medicament for adjusting organism immunity of tumor patients
CN110339276A (en) Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof
CN106039196B (en) A pharmaceutical composition for treating hyperlipidemia
CN103638456A (en) Traditional Chinese medicine for treating liver cirrhosis and preparation method for same
CN104225016B (en) A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis
CN109125489A (en) A kind of pharmaceutical composition and its preparation method and application for treating tumour and leukaemia
CN104069463B (en) A kind of Chinese drugs agentia for treating gynaecologic metrorrhagia
CN105435134A (en) Chinese herbal preparation for treating stomach cancer together with chemotherapeutic drugs
CN104825817A (en) Traditional Chinese medicine preparation with antitumor effect
CN104825922A (en) Traditional Chinese medicine composition with anti-colorectal cancer activity and preparation method and application of traditional Chinese medicine composition
CN104398920A (en) Drug for consolidating effects of radiotherapy and chemotherapy of cervical cancer and preparation method of drug
CN109078157A (en) A kind of anti-tumor drug and preparation method thereof
CN109010660A (en) A kind of Chinese medicine composition and preparation method thereof improving chemotherapy patients' hematocrit level
CN114869987B (en) Traditional Chinese medicine composition for preventing liver cancer
CN101391074B (en) Medicine composition for treating digestive system carcinoma and preparation method thereof
CN102091181A (en) Chinese medicinal composition for treating acute and chronic granulocytic leukemia 1 and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190104

RJ01 Rejection of invention patent application after publication